

10/589646
Rec'd PCT/PTO 16 AUG 2006
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Jilly Evans, et al.	
Serial No.:	To Be Assigned	Case No.: 21238YP
US Nat'l Filing Date:	August 10, 2006	
Int'l Appl'n No.	PCT/US2005/005683	
Int'l Filing Date:	24 February 2005	
For:	USE OF CYSTEINYL LEUKOTRIENE 2 RECEPTOR ANTAGONISTS	

Mail Stop PCT
Commissioner for Patents
P.O. BOX 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT August 16, 2006
EXPRESS MAIL NO. EL 019585504US

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail "Post Office to Addressee" on the above date in an envelope addressed to:

Commissioner for Patents, P. O. Box 1450,
Alexandria, Virginia 22313-1450

MAILED BY Don Schepisi
DATE 8-16-06

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.


In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Reference E on the accompanying PTO 1440 form was cited in the International Search Report for this application. A copy of the International Search Report and Written Opinion of the International Searching Authority is enclosed with the Information Disclosure Statement.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application. Accordingly, it is believed that no fee is due.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By 
John C. Todaro, Reg. No. 36,036
Attorney for Applicant

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-0125

Date: August 16, 2006

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				COMPLETE IF KNOWN	
				Application Number	To Be Assigned 10/589646
				Filing Date	August 16, 2006
				First Named Inventor	Jilly Evans
				Group Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	1	of	3	Attorney Docket Number	21238YP

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			COMPLETE IF KNOWN		
			Application Number	To Be Assigned 01/589646	
			Filing Date	August 16, 2006	
			First Named Inventor	Jilly Evans	
			Group Art Unit	To Be Assigned	
			Examiner Name	To Be Assigned	
Sheet	2	of	3	Attorney Docket Number	21238YP

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	E	Database PUBMED on GOOGLE, Neurosurgical Clinic, Justus-Liebig University Giessen, (Germany), WINKING, M. et al., "Levels of Immunoreactive cysteinyl-leukotrienes in CSF after subarachnoid haemorrhage correlate with blood flow-velocity in TCD", abstract, Acta Neurochir (Wein), 139(8):764-769 (1997)
	F	J. Takasaki et al., "The Molecular Characterization and Tissue Distribution.....," Biochemical and Biophysical Research Communications, Vol. 274, pp. 316-322 (2000)
	G	M. Kamohara et al., "Functional Characterization of Cysteinyl Leukotriene.....," Biochemical and Biophysical Research Communications, Vol. 287, pp. 1088-1092 (2001)
	H	J. Zhu et al., "Localization and Upregulation of Cysteinyl Leukotriene-1 Receptor in Asthmatic Bronchial Mucosa," Am J Respir Cell Mol Biol., Vol. 33, pp. 531-540 (2005)
	I	G. Yang et al., "Transgenic smooth muscle expression of the human.....," Am J Physiol Lung Cell Mol Physiol., Vol. 286, pp. L992-1001 (2004)
	J	K. Lotzer et al., "Differential Leukotriene Receptor Expression and Calcium Responses in Endothelial Cells and Macrophages Indicate.....," Arterioscler Thromb Basc Biol., Vol. 23, No. 8, pp. e32-6 (2003)
	K	Galczenski et al., "Characterization of DUO-LT, a Novel Dual Cysteinyl Receptor Antagonist," presented at American Thoracic Society Meeting (April 2002)
	L	H. Nothacker et al., "Molecular Cloning and Characterization of a Second Human Cysteinyl Leukotriene Receptor: Discovery of a Subtype Selective Agonist," Molecular Pharmacology, Vol. 58, No. 6, pp. 1601-1608 (2000)
	M	C. Heise et al., "Characterization of the Human Cysteinyl Leukotriene 2 Receptor," J of Biological Chemistry, Vol. 275, No. 39, pp. 30531-30536 (2000)
	N	H. Ogasawara et al., "Characterization of Mouse Cysteinyl Leukotriene Receptors mCystLT1 and mCysLT2", J of Biol Chem, Vol. 277, No. 21, pp. 18763-18768 (2002)
	O	M. Golden et al., "Protection from Pulmonary Fibrosis in Leukotriene-Deficient Mice," Am J Respir Crit Care Med., Vol. 165, pp. 229-235 (2002)
	P	J. Wilborn et al., "Constitutive Activation of 5-Lipoxygenase in the Lungs of Patients with Idiopathic Pulmonary Fibrosis," J. Clin. Invest., Vol. 97, No. 8, pp. 1827-1836 (1996)
	Q	A. DiGennaro et al., "Cysteinyl-luekotriene receptor activation in brain inflammatory reactions and cerebral edema formation.....," The FASEB Journal express article 10.1096/fj.03-0599fje. Published online March 4, 2004.
	R	A. DiGennaro et al., "Cysteinyl-leukotrienes receptor activation in brain inflammatory reactions and cerebral brain edema formation:.....," FASEB, Vol. 18, pp. 842-844 (May 2004)
	S	L. Zhao et al., "The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm," Nature Medicine, Vol. 10, No. 9, pp. 966-973 (2004)

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet

**Examiner
Initials***

**Cite
No.**

Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.

T

T. Beller et al., "Cysteinyl leukotriene 1 receptor controls the severity of chronic pulmonary inflammation and fibrosis," PNAS, Vol. 101, No. 9, pp. 3047-3052 (2004)

**Examiner
Signature**

Date
Considered

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005